BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30373175)

  • 1. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
    Khandelwal S; Boylan M; Spallholz JE; Gollahon L
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Potential of Conjugated Selenium Redox Folic Acid as a Treatment for Triple Negative Breast Cancer.
    Khandelwal S; Boylan M; Kirsch G; Spallholz JE; Gollahon LS
    Antioxidants (Basel); 2020 Feb; 9(2):. PubMed ID: 32033374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474.
    Bapat P; Sewell DG; Boylan M; Sharma AK; Spallholz JE
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
    Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
    J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
    Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
    Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody drug conjugates for patients with breast cancer.
    Medford A; Spring LM; Moy B; Bardia A
    Curr Probl Cancer; 2021 Oct; 45(5):100795. PubMed ID: 34635342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
    Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
    Amoury M; Bauerschlag D; Zeppernick F; von Felbert V; Berges N; Di Fiore S; Mintert I; Bleilevens A; Maass N; Bräutigam K; Meinhold-Heerlein I; Stickeler E; Barth S; Fischer R; Hussain AF
    Oncotarget; 2016 Aug; 7(34):54925-54936. PubMed ID: 27448975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
    Sharma R; Kameswaran M; Pandey U; Dash A
    J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
    Liu D; Cardillo TM; Wang Y; Rossi EA; Goldenberg DM; Chang CH
    Mol Cancer; 2014 Mar; 13():53. PubMed ID: 24606732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.